
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, I will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **IGF2 (Insulin-like Growth Factor 2):** Involved in growth and development, often overexpressed in various cancers.<br>- **COL2A1 (Collagen Type II Alpha 1 Chain):** A major component of cartilage, indicating potential mesenchymal or stromal cell involvement.<br>- **PTGDS (Prostaglandin D2 Synthase):** Involved in prostaglandin synthesis, often associated with immune modulation.<br>- **HSPB6 (Heat Shock Protein Family B Member 6):** A small heat shock protein involved in stress response.<br>- **SNAI2 (Snail Family Transcriptional Repressor 2):** A transcription factor involved in epithelial-mesenchymal transition (EMT), often linked to cancer metastasis.<br>- **FABP5 (Fatty Acid Binding Protein 5):** Involved in fatty acid transport, often associated with cancer cell metabolism.<br>- **VIM (Vimentin):** A marker of mesenchymal cells, often used to identify cells undergoing EMT.<br><br>### Step 2: List the Key Cell Type Markers<br>- **ACAN (Aggrecan):** A cartilage-specific proteoglycan, indicating chondrocyte or mesenchymal origin.<br>- **BGN (Biglycan):** A small leucine-rich repeat proteoglycan, often found in connective tissues.<br>- **CRABP1 (Cellular Retinoic Acid Binding Protein 1):** Involved in retinoic acid signaling, often expressed in neural and mesenchymal cells.<br>- **S100A1 (S100 Calcium Binding Protein A1):** Often expressed in muscle and neural tissues.<br>- **SDC2 (Syndecan 2):** A cell surface proteoglycan involved in cell adhesion and migration, often expressed in mesenchymal cells.<br>- **CHI3L1 (Chitinase 3 Like 1):** Involved in tissue remodeling and inflammation, often expressed in macrophages and cancer-associated fibroblasts.<br>- **MFAP2 (Microfibril Associated Protein 2):** Associated with elastic fiber assembly, often found in connective tissues.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and literature on scRNA-seq datasets, the markers suggest a mesenchymal or stromal cell type, potentially cancer-associated fibroblasts (CAFs) or mesenchymal stem cells (MSCs).<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of markers like VIM, COL2A1, ACAN, and SNAI2, the most probable general cell type is **mesenchymal cells**. These markers are indicative of cells involved in structural support and tissue remodeling, common in the tumor microenvironment.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Cancer-Associated Fibroblasts (CAFs):** Highly likely due to the expression of markers like VIM, SNAI2, and CHI3L1, which are associated with the tumor stroma and EMT.<br>2. **Mesenchymal Stem Cells (MSCs):** Possible due to the presence of markers like ACAN and COL2A1, which are indicative of a chondrogenic lineage.<br>3. **Chondrocytes:** Less likely but possible due to the expression of ACAN and COL2A1, which are specific to cartilage.<br><br>The most likely subtype based on the markers is **Cancer-Associated Fibroblasts (CAFs)**, given their role in the tumor microenvironment and the expression of EMT-related markers.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of mesenchymal cells, specifically cancer-associated fibroblasts (CAFs). This conclusion is supported by the expression of markers associated with EMT, tissue remodeling, and the tumor microenvironment. The presence of markers like VIM, SNAI2, and CHI3L1 strongly indicates a role in cancer progression and stromal support.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency:**<br>   - The markers used in the annotation (e.g., IGF2, ACAN, COL2A1, PTGDS, SNAI2, VIM, CHI3L1) are present in the provided marker list.<br>   - The markers are consistent with the identified cell type, as they are commonly associated with mesenchymal cells and cancer-associated fibroblasts (CAFs). For example, VIM and SNAI2 are well-known markers for mesenchymal cells and EMT, while CHI3L1 is associated with cancer-associated fibroblasts.<br><br>2. **Mixed Cell Type Consideration:**<br>   - The annotation considers the possibility of mixed cell types by identifying potential subtypes such as mesenchymal stem cells (MSCs) and chondrocytes. However, the strongest evidence supports the presence of cancer-associated fibroblasts (CAFs), which aligns with the tumor microenvironment context of breast cancer tissue.<br><br>The annotation process has been thorough, considering both the general cell type and potential subtypes, and the conclusion of cancer-associated fibroblasts is well-supported by the marker evidence.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">mesenchymal cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Cancer-Associated Fibroblasts (CAFs)</li><li>Mesenchymal Stem Cells (MSCs)</li><li>Chondrocytes</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">85</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a well-structured approach to identifying the cell types present in the single-cell dataset derived from human breast cancer tissue. The analysis effectively utilizes a range of markers to determine the most probable cell types, focusing on mesenchymal cells and specifically cancer-associated fibroblasts (CAFs). Here are the strengths and weaknesses identified in the annotation:<br><br>**Strengths:**<br><br>1. **Comprehensive Marker Analysis:** The annotation process considers a wide array of markers, such as IGF2, ACAN, COL2A1, PTGDS, SNAI2, and VIM, which are relevant to the identification of mesenchymal cells and CAFs. This broad consideration helps in capturing the complexity of the cell population.<br><br>2. **Balanced Consideration:** The analysis does not overly focus on a single marker but rather integrates multiple markers to support the conclusion. For instance, the presence of VIM and SNAI2, both associated with epithelial-mesenchymal transition (EMT), strengthens the identification of CAFs.<br><br>3. **Contextual Understanding:** The annotation takes into account the tumor microenvironment context of breast cancer tissue, which is crucial for understanding the role of CAFs in cancer progression.<br><br>4. **Consideration of Subtypes:** The identification of potential subtypes, such as mesenchymal stem cells (MSCs) and chondrocytes, shows an understanding of the possible heterogeneity within the cell population.<br><br>**Weaknesses:**<br><br>1. **Marker Ranking Consideration:** While the analysis is comprehensive, it could have placed more emphasis on the ranking of markers. For example, IGF2 appears first in the list, suggesting its potential importance, but its role is not as prominently discussed in the context of mesenchymal cells or CAFs.<br><br>2. **Potential Overlook of Other Cell Types:** Although the focus on mesenchymal cells and CAFs is well-supported, there might be an oversight of other potential cell types that could be present, given the diverse marker list.<br><br>3. **Lack of Specificity in Subtype Identification:** While the annotation identifies potential subtypes, the justification for the likelihood of each subtype could be more detailed, particularly for chondrocytes, which are deemed less likely.<br><br>Overall, the annotation is scientifically accurate and provides a comprehensive view of the cell types present, with a strong focus on mesenchymal cells and CAFs. However, a more detailed consideration of marker ranking and potential other cell types could enhance the analysis.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    